

Lurbinectedin



Included Products: Zepzelca (lurbinectedin)

Nonformulary for outpatient benefit. PA required on medical benefit.

Created: 08/03/2020

Revised: 03/10/2022

Reviewed: 03/10/2022

Updated: 04/01/2022

Cancer			
Initial Criteria		If yes	If no
1.	Is the request by an oncologist?	Continue to #2.	Do not approve.
2.	Is the request for a patient with small cell lung cancer (SCLC)?	Continue to #3.	Review for NCCN support.
3.	Does the patient have evidence of CNS involvement on imaging?	Do not approve. Use is investigational.	Continue to #4.
4.	Has the patient been previously treated with a platinum-based chemotherapy?	Continue to #5.	Do not approve. Use is investigational.
5.	Did the patient have a relapse within 6 months?	Continue to #6.	Continue to #7.
6.	Has the patient failed topotecan IV?	Continue to #7.	Do not approve. Criteria not met, must fail topotecan IV.
7.	Approve for 12 months.		
Renewal Criteria		If yes	If no
1.	Has there been evidence of tumor response?	Continue to #2.	Do not approve.
2.	Has the patient received chemotherapy since starting Zepzelca?	Pend for provider statement.	Continue to #3.
3.	Approve for 12 months.		

Continued >>

Subsequent Renewal Criteria		If yes	If no
1.	Has there been evidence of tumor response?	Continue to #2.	Do not approve.
2.	Approve for 12 months.		